Iguana Healthcare Management LLC bought a new stake in Paratek Pharmaceuticals Inc (NASDAQ:PRTK) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 35,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $879,000. Iguana Healthcare Management LLC owned approximately 0.13% of Paratek Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Cadence Capital Management LLC acquired a new stake in shares of Paratek Pharmaceuticals in the second quarter valued at about $562,000. Royce & Associates LP grew its stake in shares of Paratek Pharmaceuticals by 113.3% in the second quarter. Royce & Associates LP now owns 282,900 shares of the specialty pharmaceutical company’s stock valued at $6,818,000 after buying an additional 150,300 shares in the last quarter. Omni Partners LLP acquired a new stake in shares of Paratek Pharmaceuticals in the third quarter valued at about $3,707,000. Marshall Wace LLP acquired a new stake in shares of Paratek Pharmaceuticals in the second quarter valued at about $942,000. Finally, Alps Advisors Inc. acquired a new stake in shares of Paratek Pharmaceuticals in the second quarter valued at about $598,000. Institutional investors and hedge funds own 84.30% of the company’s stock.

PRTK has been the subject of a number of analyst reports. BidaskClub downgraded Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 23rd. Cantor Fitzgerald reissued a “buy” rating and issued a $50.00 price target on shares of Paratek Pharmaceuticals in a report on Wednesday, August 23rd. Raymond James Financial reissued a “strong-buy” rating and issued a $36.00 price target on shares of Paratek Pharmaceuticals in a report on Thursday, August 24th. ValuEngine downgraded Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, September 18th. Finally, Zacks Investment Research downgraded Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $40.00.

Paratek Pharmaceuticals Inc (NASDAQ PRTK) opened at $17.45 on Friday. Paratek Pharmaceuticals Inc has a 1-year low of $13.15 and a 1-year high of $29.00. The company has a quick ratio of 10.53, a current ratio of 10.53 and a debt-to-equity ratio of 0.49.

COPYRIGHT VIOLATION WARNING: “35,000 Shares in Paratek Pharmaceuticals Inc (PRTK) Purchased by Iguana Healthcare Management LLC” was first reported by Daily Political and is the property of of Daily Political. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/12/15/35000-shares-in-paratek-pharmaceuticals-inc-prtk-purchased-by-iguana-healthcare-management-llc.html.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Want to see what other hedge funds are holding PRTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Paratek Pharmaceuticals Inc (NASDAQ:PRTK).

Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.